Glucagon-Like Peptide-1 Receptor Agonists and Vascular Protection: Mitigating Systemic and Ocular Risks in High-Risk Type 2 Diabetes
Highlights
- GLP-1 receptor agonists (GLP-1 RAs) are associated with a 35% reduction in myocardial infarction and a 22% reduction in ischemic stroke in T2D patients with retinopathy.
- Ocular protection: The use of GLP-1 RAs reduced the risk of progression to proliferative diabetic retinopathy (PDR) by 22% and retinal vein occlusions (RVO) by 30%.
- Renal benefits were profound, with a 60% reduction in the need for renal replacement therapy (RRT).
- The data suggest GLP-1 RAs do not increase the risk of NAION or retinal artery occlusions, addressing long-standing clinical concerns.
Background
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.